Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v6-FR
Language French French
Date Updated 2020-07-16 2019-12-11
Drug Identification Number 02253631 02253631
Brand name TEVETEN PLUS TEVETEN PLUS
Common or Proper name TEVETEN PLUS TEVETEN PLUS
Company Name BGP PHARMA ULC BGP PHARMA ULC
Ingredients HYDROCHLOROTHIAZIDE EPROSARTAN HYDROCHLOROTHIAZIDE EPROSARTAN
Strength(s) 12.5MG 600MG 12.5MG 600MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 2x14CA 2x14CA
ATC code C09DA C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date
Actual start date 2019-11-18 2019-11-18
Estimated end date Unknown Unknown
Actual end date 2020-07-10
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments